Test-retest reliability of the Impact of Vision Impairment-Very Low Vision questionnaire

• Verfasst von: Fink, David [VerfasserIn]
• Verfasst von: Terheyden, Jan H. [VerfasserIn]
• Verfasst von: Pondorfer, Susanne G. [VerfasserIn]
• Verfasst von: Holz, Frank G. [VerfasserIn]
• Verfasst von: Finger, Robert P. [VerfasserIn]
• Titel: Test-retest reliability of the Impact of Vision Impairment-Very Low Vision questionnaire
• Titelzusatz: retina
• Verf.angabe: David J. Fink, Jan H. Terheyden, Susanne G. Pondorfer, Frank G. Holz, and Robert P. Finger
• E-Jahr: 2023
• Jahr: June 12, 2023
• Umfang: 7 S.
• Fussnoten: Gesehen am 07.10.2024
• Titel Quelle: Enthalten in: Translational Vision Science & Technology
• Ort Quelle: Rockville, Md. : ARVO, 2012
• Jahr Quelle: 2023
• Band/Heft Quelle: 12(2023), 6 vom: Juni, Artikel-ID 6, Seite 1-7
• ISSN Quelle: 2164-2591
• DOI: doi:10.1167/tvst.12.6.6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1904849865

Abstract

Most patient-reported outcome measures used in ophthalmology show floor effects in a very low vision population, which limits their use in vision restoration trials. The Impact of Vision Impairment-Very Low Vision scale (IVI-VLV) was developed to specifically target a very low vision population, but its test-retest reliability has not been investigated yet. The German version of the IVI-VLV was administered twice to patients with stable disease of a low vision clinic. Test and retest person measures of the IVI-VLV subscales were obtained from Rasch analysis. Test-retest reliability was investigated by intraclass correlation coefficients and Bland-Altman plots. We included 134 patients (72 women, 62 men) at a mean age of 62 ± 15 years. The intraclass correlation coefficients were 0.920 (95% confidence interval, 0.888-0.944) for the activities of daily living and mobility subscale of the IVI-VLV and 0.929 (95% confidence interval, 0.899-0.949) for the emotional well-being subscale. Bland-Altman plots did not indicate any systematic bias. In linear regression analysis, test-retest differences were not significantly associated with visual acuity or administration interval. Both subscales of the IVI-VLV showed excellent repeatability independent of visual acuity and length of repeat interval. Further validation steps including an assessment of the patient-reported outcome measure's responsiveness are required for use in vision restoration trials. The results support repeated use of the IVI-VLV as a patient-reported end point in future studies in very low and ultralow vision populations.